Standout Papers
Citation Impact
Citing Papers
p53: puzzle and paradigm.
1996 Standout
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Hallmarks of Cancer: The Next Generation
2011 Standout
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.
1993
A checkpoint regulates the rate of progression through S phase in S. cerevisiae in Response to DNA damage
1995 StandoutNobel
Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
1995
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
1997 Standout
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
1999
Inflammation and cancer
2002 StandoutNature
Regulation of p53 stability by Mdm2
1997 StandoutNature
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
1995 Nature
WAF1, a potential mediator of p53 tumor suppression
1993 Standout
Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
1992 StandoutNobel
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
p53 in growth control and neoplasia
1996
Tumor spectrum analysis in p53-mutant mice
1994 Standout
Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1
1997
The complexity of p53 modulation: emerging patterns from divergent signals
1998
DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2
1997 Standout
The Spectrum of Mutations at the p53 Locus
1995
Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors
2006 StandoutNobel
Allosteric activation of latent p53 tetramers
1994
The ubiquitin-proteasome proteolytic pathway
1994 StandoutNobel
Tumor surveillance via the ARF–p53 pathway
1998
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
1998 StandoutNatureNobel
What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?
1993
Synergistic activation of transcription by CBP and p53
1997 Nature
When Checkpoints Fail
1997 StandoutNobel
Tumor-suppressor p53 and the cell cycle
1993
The Hallmarks of Cancer
2000 Standout
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011 StandoutNatureNobel
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
1993 Nature
MDM2 function
1998
A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer
2000
COMMENTARY: p53 Tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective
1996
Tumor suppressor genes
1994
SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1α ubiquitination and degradation
2007 StandoutNobel
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
1992 Standout
p300/MDM2 Complexes Participate in MDM2-Mediated p53 Degradation
1998
DNA damage induces phosphorylation of the amino terminus of p53
1997
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
2003
The C. elegans Protein EGL-1 Is Required for Programmed Cell Death and Interacts with the Bcl-2–like Protein CED-9
1998 StandoutNobel
The p53–Mdm2 module and the ubiquitin system
2002
Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis
1997
Regulation of the Sequence-specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases
1995
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
1997
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
1999 StandoutNatureNobel
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
1992
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation
1998
The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2
1998
The MDM2 gene amplification database
1998
E1A signaling to p53 involves the p19ARFtumor suppressor
1998
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht
2000
Clinical Implications of the p53 Tumor-Suppressor Gene
1993
Interaction between the retinoblastoma protein and the oncoprotein MDM2
1995 Nature
ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways
1998
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
1996 StandoutNobel
p73 is a human p53-related protein that can induce apoptosis
1997 StandoutNatureNobel
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
1995 Nature
p53 function and dysfunction
1992 Standout
Transcriptional activation by p53 correlates with suppression of growth but not transformation
1994
A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation
1996
Gal80-Gal80 interaction on adjacent Gal4p binding sites is required for complete GAL gene repression
2001
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
1999 StandoutNobel
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
1995 Nature
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
1999
Gain of function mutations in p53
1993
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
1993 Standout
The Gut-enriched Krüppel-like Factor (Krüppel-like Factor 4) Mediates the Transactivating Effect of p53 on the p21 Promoter
2000
Genomic instability — an evolving hallmark of cancer
2010 Standout
CDC5 and CKII Control Adaptation to the Yeast DNA Damage Checkpoint
1997 StandoutNobel
The Emerging p53 Gene Family
1999 StandoutNobel
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
1997
p53 in signaling checkpoint arrest or apoptosis
1996
The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53
1998
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
1992
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
1995 Standout
Regulation of the specific DNA binding function of p53
1992
Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer
1996
Repression of p53-mediated transcription by MDM2: a dual mechanism
1997
Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease
2007 StandoutNobel
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
1996
A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein
1997
Wild-type p53 binds to the TATA-binding protein and represses transcription.
1992
Life, death, and the pursuit of apoptosis.
1996
Regulation of Mdm2-Directed Degradation by the C Terminus of p53
1998
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
1999
Analysis of a Protein-Binding Domain of p53
1993
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
2000 StandoutNobel
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.
1995
The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain
1996
Human TAFII31 protein is a transcriptional coactivator of the p53 protein.
1995
The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth.
1994 StandoutNobel
The mdm-2 gene is induced in response to UV light in a p53-dependent manner.
1993
Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems
1999 Nobel
Absence of WAF1 mutations in a variety of human malignancies
1994
Regulation of Receptor Fate by Ubiquitination of Activated β 2 -Adrenergic Receptor and β-Arrestin
2001 StandoutScienceNobel
Mechanisms of DNA Excision Repair
1994 StandoutScienceNobel
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.
1994
Analysis of the degradation function of Mdm2.
1999
Cancer Cell Cycles
1996 StandoutScience
Cyclin G is a transcriptional target of the p53 tumor suppressor protein.
1994
Cell Cycle Control and Cancer
1994 StandoutScienceNobel
p53 and E2F-1 cooperate to mediate apoptosis.
1994
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
1994
mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein
1996
MDM2 Suppresses p73 Function without Promoting p73 Degradation
1999 StandoutNobel
Mdm-2: “big brother” of p53
1997
Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene
1995
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
1995
A General Mechanism for Network-Dosage Compensation in Gene Circuits
2010 StandoutScienceNobel
DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells.
1994
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway.
1994
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
1998
The potential tumor suppressor p73 differentially regulates cellular p53 target genes.
1998
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
1993
p53 Transcriptional Activation Mediated by Coactivators TAF II 40 and TAF II 60
1995 Science
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Mapping of the p53 and mdm-2 Interaction Domains
1993
mdm2 expression is induced by wild type p53 activity.
1993
p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
1998
The p53 tumor suppressor protein: meeting review.
1993
The p53 Activation Domain Binds the TATA Box-Binding Polypeptide in Holo-TFIID, and a Neighboring p53 Domain Inhibits Transcription
1993
Growth factor modulation of p53-mediated growth arrest versus apoptosis.
1995
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
1997 Standout
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
1994
Regulation of p53 stability
1999
Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6
1998
Accumulation of p53 in a Mutant Cell Line Defective in the Ubiquitin Pathway
1994
p53 binds to the TATA-binding protein-TATA complex
1993
Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
1996
Non-p53 p53RE binding protein, a human transcription factor functionally analogous to P53
1998
SAG/ROC2/Rbx2 Is a Novel Activator Protein-1 Target that Promotes c-Jun Degradation and Inhibits 12-O-Tetradecanoylphorbol-13-Acetate–Induced Neoplastic Transformation
2007
The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells
1994
The mdm-2 Oncogene Can Overcome Wild-Type p53 Suppression of Transformed Cell Growth
1993
Human DNA Repair Genes
2001 StandoutScienceNobel
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
1994
The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis
2000
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
1998 StandoutScience
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.
1993
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
The gadd and MyD Genes Define a Novel Set of Mammalian Genes Encoding Acidic Proteins That Synergistically Suppress Cell Growth
1994 StandoutNobel
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
1994
Mapping of the p53 and mdm-2 interaction domains.
1993
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53
1993
The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2
1996
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
1998
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
1998
Works of David C. Olson being referenced
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
1992 Standout
The p53-mdm-2 autoregulatory feedback loop.
1993 Standout
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
1993